Posttreatment cardiotoxity in patient with lymphoma

Abstract

Efficacy of anti-lymphoma therapy, prolonging significantly overall survival, allows us to observe late adverse effects of antineoplastic drugs. Cardiotoxicity of anthracyclins is dose dependent and increasing with time elapsed after therapy. It is more pronounced in patients with pre-existing heart disorders, treated with combined chemotherapy regimens or concomitant mediastinal radiotherapy. Cardiotoxic effects may be attenuated by using regimens with a low cumulative dose of anthracyclins, their liposomal formulations or cardioprotective substances.
Onkol. Prak. Klin. 2010; supl. A: A18–A24